Approval · Notice of Compliance 28465 · 2022
TOPAMAX: Notice of Compliance 28465
Issued June 27, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 28465
- Date
- June 27, 2022
- Company
- Janssen Inc.Toronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Safety Update and conversion to the 2020 PM Master template.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TOPAMAX | Not yet assigned | — |
Medicinal ingredients
- TOPIRAMATE 15 MG per CAP
- TOPIRAMATE 25 MG per CAP
- TOPIRAMATE 25 MG per TAB
- TOPIRAMATE 100 MG per TAB
- TOPIRAMATE 200 MG per TAB